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Abstract
Background: A computer controlled infusion pump (UIPump) for regulation of target tissue
concentration of radioactive compounds was developed for use in biological research and tracer
development for PET.
Methods: Based on observed tissue or plasma kinetics after a bolus injection of the tracer an
algorithm calculates the infusion needed to obtain a specified target kinetic curve. A computer
feeds this infusion scheme into an infusion pump connected to an animal via a venous catheter. The
concept was validated using [11C]Flumazenil administrated to Sprague-Dawley rats where the
whole brain distribution and kinetic of the tracer was measured over time using a microPET-
scanner. The accuracy and precision of the system was assessed by producing steady-state levels
of the tracer and by mimicking kinetics after oral administration.
Results: Various kinetic profiles could be generated, including rapid achievement of constant
levels, or step-wise increased levels. The resulting tissue curves had low deviation from the target
curves according to the specified criteria: AUC (%): 4.2 ± 2.8, Maximal deviation (%): 13.6 ± 5.0
and R2: 0.95 ± 0.02.
Conclusion: The UIPump-system is suitable for use in PET-research for assessment of PK/PD
properties by simulation of different tracer tissue kinetics in vivo.
Background
Functional imaging for the assessment of the in vivo phar-
macokinetics and pharmacodynamics (PK/PD) of drugs
either preclinically or in early clinical trials has become an
important step in pharmacological research and drug
development. Positron Emission Tomography (PET) is a
noninvasive imaging tool that allows the assessment of
PK/PD parameters directly at the level of the drug target,
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as opposed to traditional models where tissue PK/PD is
estimated indirectly via knowledge of plasma concentra-
tions and/or through measurements of biomarkers as
indicators of target modulation. With the administration
of radiolabeled drugs, PET allows the direct measurement
of tissue concentration of radioactivity, and through
knowledge of the specific radioactivity, ratio of radioactiv-
ity concentration and concentration of non-radioactive
compound, the drug concentration kinetic profile can be
obtained with high accuracy. Alternatively, with the
administration of a PET tracer with high affinity and spe-
cificity for the target, parameters can be extracted from the
tissue kinetic profiles which are relevant for target expres-
sion, notably binding potential which is proportional to
Bmax/kD.
During a tissue PK PET scan the labeled drug is commonly
administered to the subject by an i.v. bolus injection. After
the absorption phase, the tracer level in tissue reaches a
maximum and usually starts to decrease due to metabo-
lism and/or washout. Eventually, the tracer is eliminated
through the main excretion routes, the liver or the kidney
and the urinary bladder. However, most drugs are admin-
istered orally which generates an entirely different tissue
kinetics as compared to i.v. By recording the kinetics of
radioactivity in plasma during the PET scan, the exchange
parameters between plasma and tissue can be estimated
and applied on the plasma PK from the oral drug admin-
istration and thereby calculate the tissue PK of the cold
drug [1]. Alternatively it should be possible to generate an
i.v. administration scheme which simulates the PK profile
obtained from oral administration and thereby direct
observe the proper tissue concentration profile in the PET
study.
A concept has been suggested in which the radiotracer is
administered such to obtain a steady state in tissue and
hence constitute the baseline, from which perturbations
due to for example a blocking compound, can be identi-
fied and consequently quantified.
Various methods have been used to approach the issue of
controlling blood concentrations of drugs or tracers. Usu-
ally, these techniques have aimed to achieve a steady state
concentration of the radiotracer/compound in the blood/
plasma. The most common approach is the bolus injec-
tion followed by a constant infusion [2-4]. This method is
simple but has some drawbacks; it often takes some time
until steady-state is achieved, with over- or under-expo-
sures at early time points, and may yield large deviations
from targeted concentrations after long time periods. This
approach works well if you are only interested in achiev-
ing a steady state of a radiotracer in the plasma or in some
target tissue. It can not be used to produce more complex
TACs. This method also usually needs more time to reach
the steady state, at least if the bolus curve is decaying expo-
nentially which usually is the case. Constant subsequent
infusion can not compensate well for the washout in this
case. If the bolus curve would decay linearly however,
then constant infusion would compensate perfectly.
Target controlled infusion (TCI)-systems usually aim to
set the tissue concentration of a drug to a steady state level
by administrating a bolus followed by exponentially
declining infusion rates, where the subsequent infusion
parameters are determined from a model of the PK/PD
parameters of the compound in the subject [5,6]. This
method has been sparsely used in combination with PET
[7].
In this study we present a novel approach for controlling
tissue concentration of either drug or PET tracer in a PET
study. The method is versatile and can be applied with a
variety of tracers in different tissues and allows an arbi-
trary tissue kinetic curve to be generated. The computer-
ized infusion system, UIpump, utilizes an algorithm that
compensates for the difference between the bolus curve
and the finally desired curve at each discrete time point.
The method is designed to infuse a short bolus injection
followed by subsequent discrete infusions. The subse-
quent discrete infusions are designed to compensate the
elimination of the tracer by modifying the concentration
to the level of the desired curve. The tissue level of radio-
activity and mass concentration can be determined at will
and hence the total administered amount (μg/kg) over an
entire study can be ensured to be below toxicity levels
respectively such as the tracer dose by itself is not perturb-
ing the target system [8]. The concept was validated using
a well known radiotracer, [N-methyl-11C]flumazenil
which binds to central benzodiazepine receptors (BZR)
with high affinity and specificity.
Methods
Radiochemistry
[N-methyl-11C]flumazenil ([11C]-ROB) is a selective cen-
tral BZR antagonist [9] and the most extensively used BZR
tracer for PET. [11C]ROB was synthesized as described pre-
viously [10]. The radiochemical purity of each batch was
greater than 95%. The specific radioactivity was typically
52 ± 20 MBq/nmol.
Animals
Adult male Sprague-Dawley rats weighing 450–600 g were
housed under standard laboratory conditions (20°C and
50% humidity) and maintained under a 12-h light-dark
cycle with free access to food and water. The animal stud-
ies were approved by the local Research Animal Ethics
Committee (permission C 153/4). Animals were initially
anesthetized using 3.2% isoflurane and continuous
anesthesia was maintained by 2.4% isoflurane (600 ml/hBMC Medical Physics 2008, 8:2 http://www.biomedcentral.com/1756-6649/8/2
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air) through a face mask. Temperature was measured and
breathing rate was monitored visually. Radiotracers were
administered through an i.v. catheter in the tail-vein.
Infusion pump system
The UIpump system consists of a programmable Univen-
tor 864 Infusion Pump (AgnThos, Sweden) connected to
a personal computer. The infusion pump is controlled by
UIPump, a custom made Visual Basics-based program on
the PC.
Calculation of the UIPump input function is performed
through the following equations:
Ctarget (t) = HTR(t)  Cinfusion (t)
where Cinfusion defines the infusion rate from the pump,
Ctarget the tissue kinetics and HTR the pump function. The
pump function (impulse response) is a reflection of how
the body is handling an infinitesimally short exposure,
but also includes aspects of the pump and tubing.
If Cinfusion is a short intravenous injection (<5 seconds) it
can be approximated to be a Dirac impulse, δ(t), which
allows the pump function to be derived from the tissue
kinetic curve obtained from this bolus injection.
Ctarget-bolus (t) = HTR(t)  δ(t) = HTR (t)
where  is a convolution operator. The intravenous input
Cinfusion needed to achieve an arbitrarily chosen Ctarget can
now be determined from
Ctarget (t) = HTR(t)  Cinfusion (t)
where HTR is known from the bolus-experiment and Ctarget
is a designed target tissue concentration curve. HTR and
Ctarget are discretized by resampling the functions at 1 sec-
ond intervals. Shorter intervals improve the accuracy but
also increase the calculation time and amount of data. Cin-
fusion is found in discrete form (also in 1 second intervals)
by deconvolution with the condition to minimize
NORM(HTR(t)  Cinfusion (t) – Ctarget (t)), where Cinfusion (t) 
≥ 0
The deconvolution is performed by using the algorithm
lsqnonneg (MatLab, MathWorks)) which solves the least
square problem with the constraint that all terms are pos-
itive or equal to zero. The solution describes the infusion
scheme in a discrete form with time intervals of 1 sec.
MicroPET studies
The imaging studies were performed using a calibrated
microPET-R4 scanner (Concorde Microsystems,
Knoxville, TN). The scanner provides a 10 × 8-cm field of
view (FOV), and the scanner is capable of an axial and
trans-axial resolution of 2 mm. A spiraling 68Ge point-
source was used to acquire 20 minute transmission scans.
3D Emission scan data were acquired in list mode without
pre-specified dynamic framing. The images were recon-
structed by using 2D filtered back projection (Hanning fil-
ter 4.0 mm). Dead time correction and random correction
were performed for all scans.
The images were analyzed using ASIPro version 3.2 (Con-
corde Microsystems Inc., Knoxville, TN). For each emis-
sion scan regions of interest (ROIs) were drawn over the
whole brain on five different coronal slices and combined
to form a volume of interest (VOI). The resulting time-
activity curves (TACTs) were normalized by dividing each
data point with the value of the point with the maximal
activity (to allow for inter-scan comparison).
Bolus Curve Acquisition
20–30 MBq/kg were administered as an i.v. bolus injec-
tion. The target tissue was monitored by PET for 60 min-
utes.
Infusion Curve Acquisition
In total 9 animals received an integrated dose of 400–600
MBq/kg over 120 minutes. The effective dose (when radi-
oactive decay is accounted for) is much smaller, with the
exact biological dose depending on the infusion scheme.
Data Analysis
The difference between the targeted curve and the result-
ing curve is one measure of the functionality and accuracy
of the infusion system. Three criteria were used to deter-
mine the discrepancies between the experimental and tar-
get curves:
AUCdiff
The area under curve (AUC) is an important concept in
pharmacology and reflects the total dose exposure in the
tissue over time. In this case AUCdiff (%) equals (AUCexp-
AUCtarget)/AUCtarget *100 and is a measure of the percent
difference of the total uptake dose.
DEVmax
The data point in the experimental data set with the larg-
est deviation compared to the target curve (in %) is
defined as the maximal deviation DEVmax. DEVmax is cal-
culated from dividing the largest deviation by the value of
the target curve at the current time point.
R2
The residual sum of squares between the experimental
and target curve was calculated as an additional control of
accuracy and precision.BMC Medical Physics 2008, 8:2 http://www.biomedcentral.com/1756-6649/8/2
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Results
Bolus Curve Acquisition
Uptake of [11C]ROB after i.v. injection was high in the
whole brain, combined with low uptake in tissues border-
ing to the brain. Highest activity levels could be seen in
the frontal cortex, thalamus and hippocampus, consistent
with the known distribution of the target molecule com-
plex, GABA-receptor (figure 1).
Bolus curves (not shown here) from i.v. injections of
[11C]ROB in four different SPD rats were averaged and
smoothed to generate an averaged bolus curve to be used
with the UIPump system (figure 2). The resulting brain
curves showed a peak within a few minutes, followed by
monoexponential elimination with a halflife of 17.3 min.
Infusion Curve Acquisition
Steady state of radiotracer in whole brain
The pump was set to ensure a constant tracer concentra-
tion in tissue for up to 120 minutes. The average of 3
experiments is demonstrated in figure 3a. Within 5 min-
utes, a value within 10% of the steady level had been
achieved, and remained close to the plateau for the
remaining time.
Generating Step Function curve in whole brain
Step function curves (n = 3) were generated using a target
curve which consisted of four increasing steady state lev-
els. The levels, 0.25, 0.5, 0.75 and 1.0 (in normalized
activity), were each 30 minutes long. The pump could
generate a nice stepwise increase of tracer in the brain,
although not with a prompt change between the levels.
Mimicking Oral Administration uptake in whole brain
Three different curves simulating delayed target tissue
uptake (compared to i.v. administration) were selected to
investigate the versatility of the infusion system. All three
experimental TACTs show the distribution of [11C]ROB in
whole brain over time which was very close to that
desired.
The implementation of UIPump for these target curves
using [11C]ROB resulted in the whole brain VOI TACTs in
figure 3a–e. The functionality and accuracy criteria for the
different experiment are presented in table 1. In general
the agreement was good between aimed and achieved
brain concentration profiles. The AUC-difference was in
most cases below 5% and the maximum deviation below
10% except in two cases where the deviations at late time
points were 20 and 17%.
Discussion
The development of a computerized pharmacokinetic
model-driven infusion device was initially investigated in
the late seventies and early eighties [11,12]. It was shown
that it was possible to attain the desired plasma concentra-
tion of an intravenously administered drug by using a
computer-controlled pump programmed with the known
pharmacokinetic properties of the drug. The UIpump
bolus curve effectively replaces the need for detailed PK
parameters, making it suitable for new and relatively
Coronal slice (summed over 45 minutes) showing brain  uptake of [11C]ROB (injected amount 24 MBq/kg) in Sprage- Dawley rat (anesthetized with 2.4% isoflurane) Figure 1
Coronal slice (summed over 45 minutes) showing 
brain uptake of [11C]ROB (injected amount 24 MBq/
kg) in Sprage-Dawley rat (anesthetized with 2.4% iso-
flurane).
Average TACT-curve after instantaneous bolus injection of  [11C]ROB in several animals Figure 2
Average TACT-curve after instantaneous bolus 
injection of [11C]ROB in several animals. The curve is 
measured over whole brain. The modeled curve is used as 
the input function for the calculation of the infusion schemes.BMC Medical Physics 2008, 8:2 http://www.biomedcentral.com/1756-6649/8/2
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a) Steady state curves (n = 3), b) Step function (4 steady state levels, n = 3), c-e) Simulating uptake after oral administration Figure 3
a) Steady state curves (n = 3), b) Step function (4 steady state levels, n = 3), c-e) Simulating uptake after oral 
administration.BMC Medical Physics 2008, 8:2 http://www.biomedcentral.com/1756-6649/8/2
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uncharacterized tracers. However, a prerequisite is that the
tissue kinetic profile is first determined with a bolus injec-
tion as a means to set the pump response function.
[11C]ROB was used as a model tracer due to its well
described PK/PD (1 tissue-compartment) and its availa-
bility. The system has been used with other tracers with
more complicated PK/PD (described by 2 tissue-compart-
ments) with promising results. However, there will be a
limit for the complexity the system can handle. The sys-
tem has not yet been tested with tracers with high non-
specific binding or tracers whose PK/PD is described with
more than two tissue compartments.
The plasma concentration of intravenous drugs or tracers
after a bolus peaks virtually instantaneously; however, the
peak brain concentration of the drug occurs later when the
brain concentration equilibrates with the central plasma
compartment. This delay is due to various biological proc-
esses (passing the blood-brain barrier etc.). For many
studies it is therefore inadequate to simply control the
plasma concentration. The UIpump system can control
either the concentration in the plasma or the concentra-
tion at the site of drug effect, depending on the study
design. Hence this system could optimize rather compli-
cated schemes with rapid switches between different lev-
els of drug in the brain.
Sometimes it may be valuable to simulate other uptake
curves. PET tracers are very seldom given orally (due to the
high concentration of radioactivity in the gastro-intestinal
tract and therefore a high local radiation dose). Uptake
curves simulating oral administration can be performed
with target controlled infusion to better simulate drugs PK
in target tissues e.g. for perturbation or blocking studies.
Blocking studies
When characterizing a novel pharmacological drug with
PET, sometimes a blocking study is performed. A target
specific tracer is administered before and after the patient
is treated with the drug. Difference in uptake compared to
a control then reveals pharmacological parameters for the
drug, but only at equilibrium in the tissue. By target con-
trolled infusion the tracer levels can be held at a steady
state while a drug is administered. Perturbations of the
steady state resulting from interactions of the drug at phar-
macological levels can be followed over time, from the
initial effect until equilibrium. This concept has been used
with our pump system to allow careful evaluation of how
drugs are affecting the PgP-system at the blood-brain-bar-
rier [13,14]. Hence the pump has ensured a constant brain
level of a tracer which is a substrate for PgP, and therefore
has limited access to the brain. At a predefined time a
challenge has been made with a pharmacological dose
with a PgP-inhibitor, allowing the tracer increase to reveal
time course and magnitude of inhibition of the PgP.
Constant levels of therapeutic doses – anesthetic agents
The use of rate-controlled delivery systems in anesthesia
has long been exploited [15,16]. Most anesthetic com-
pounds have a critical dose range. A large dose can harm
the patient, while a low dose may be insufficient for
proper anesthetic effect. Instead of monitoring the plasma
levels it can be desirable to control the concentration of
the agent in the tissue in which it exerts its effect. This is
possible when using an anesthetic agent at pharmacolog-
ical levels in combination with its radioactively labeled
version in trace amounts. An example of this application
of UIpump was described earlier [17].
Biological variation
The biological variation between individuals sets the limit
for the accuracy of the UIpump. Comparisons have shown
the difference between bolus curves to be around 10% for
Sprague-Dawley rats (data not shown here). Due to the
long anesthesia, the animals in the study are used only for
one tracer administration, preventing the bolus curve
from being obtained from the same animal as the infu-
sion curve. For studies in higher species or clinical settings
the bolus curve and the infusion regimen can be per-
formed in the same individual, which resolves this issue.
Conclusion
The UIPump system is currently in use with different trac-
ers in several animal models for preclinical PET studies. It
is a functional tool for applications in PET PK/PD experi-
mental setups.
Table 1: Difference between experimental curve and target curve for all performed studies according to three pre-specified criteria.
Target curve AUCdiff(%) MAXdev(%)* R2 Comment
Steady state (n = 3) 1.0 9.6 0.92 Figure 3a
Step function (n = 3) 6.3 12.2 0.96 Figure 3b
Oral adm. 1 4.2 8.7 0.98 Figure 3c
Oral adm. 2 1.7 20.3 0.95 Figure 3d
Oral adm. 3 7.6 17.2 0.96 Figure 3e
Average ± stdev 4.2 ± 2.8 13.6 ± 5.0 0.95 ± 0.02
*At very low concentrations (beginning of scans) even small actual errors gives very large percentual errors. The MAXdev is therefore calculated 
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